Cephalosporin Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Cephalosporin Drugs Market is segmented by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Prescription Type (Prescription Drugs and OTC Drugs) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The report offers the value (in USD million) for the above segments.

Cephalosporin Drugs Industry Overview

Study Period: 2018 - 2028
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 2.75 %

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Cephalosporin Drugs Market Analysis

The cephalosporin drugs market is expected to grow at registering a CAGR of 2.75% during the forecast period (2022-2027).

The cephalosporin market was damaged by COVID-19's effects on the pharmaceutical industry's worldwide supply chain. However, numerous antibiotics are currently explored and extensively used as a COVID-19 treatment after being initially used to treat COVID-19. Various studies have found that the higher cephalosporin consumption rate and use ratio have made lower morbidity and mortality caused by COVID-19 than another antibacterial. For instance, a research study titled "Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study" published in the PLOS ONE Journal in May 2021, Ceftaroline Fosamil, a cephalosporin antibiotic, has been proposed as a powerful inhibitor of SARS-primary CoV-2's protease responsible for processing the polyprotein translated from viral RNA. Cephalosporin has been widely used to prevent secondary bacterial infection. Also, the cephalosporins in combinations with macrolides and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore, there are in vitro and in vivo studies going on to evaluate the potential of generations of cephalosporin for COVID-19. As a result, the COVID-19 market had a significant influence and is anticipated to grow over the coming years.

The market is expected to grow due to the increasing demand for anti-microbials in various indications, the rising prevalence of infectious diseases such as HIV and tuberculosis, and the increase in funding for the development of antibiotics. For instance, according to the October 2021 report of the World Health Organization, tuberculosis is present in all countries and all age groups, and approximately 10 million people fell ill with tuberculosis (TB) all over the world in 2020, of which eight countries account for two-thirds of the total TB cases in 2021, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. It has also been reported that there is a rapid spread of various infectious diseases that is fueling market growth. Moreover, according to a survey conducted by the World Health Organization for the period from 24 January 2022 to 06 February 2022, approximately 12,368 people were positive for influenza viruses. Out of these, 8,423 (68.1%) people were typed as influenza A and 3,945 (31.9%) people as influenza B. Furthermore, 171 (6.4%) were influenza A (H1N1), and 2,483 (93.6%) were influenza A (H3N2). Thus, the growing burden of infectious diseases is expected to increase the demand for cephalosporin, thereby driving the market growth. The market growth is also attributed to the increase in consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.

Over the forecast period, the market for cephalosporin pharmaceuticals is anticipated to grow as a result of an increase in funding for research and development (R&D) of cephalosporin drugs and antibiotics. For instance, in June 2020, The International Federation of Pharmaceutical Manufacturers and Association established the AMR Action Fund, which will invest more than USD 1 billion over the coming years to support the development of urgently required new antibiotics. The fund is supported by major pharmaceutical companies and also has the support of other stakeholders. It also aims to support the development of market circumstances that will support long-term antibiotic R&D. Similarly, in June 2021, the pharmaceutical company BioVersys, located in Switzerland, received funding of up to USD 4.35 million for its efforts to create a new class of antibiotics.

Additionally, there are also companies involved in the strategic development of new products; for example, in September 2021, Lincoln Pharmaceuticals Limited intends to introduce cephalosporin medicines soon. with the acquisition of the facility in Mehsana, Gujarat, and will invest Rs. 30 crores in the modernization and capacity expansion of the cephalosporin plant. The acquisition and capital expenditures will be paid for out of internal accruals. In February 2020, Shionogi & Co. Ltd announced that FETROJA (cefiderocol) was now available in the United States for patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs). FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.

Hence, all these factors may help the cephalosporin drugs market to witness high growth over the forecast period. However, stringent regulatory approval and side effects associated with cephalosporin restrain the market growth.

Cephalosporin Drugs Industry Segments

As per the scope of this report, cephalosporins are part of the beta-lactams group and work by interfering with the synthesis of the bacterial cell wall. Some may be given orally, but most are given by injection. They are typically the second-choice antibiotic, and their main uses are in pneumonia, septicemia, meningitis, sinusitis, and UTI treatment. Despite their second-line usage, cephalosporins have a broader spectrum of activity and are more potent than penicillin. The Cephalosporin Drugs Market is segmented by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Prescription Type (Prescription Drugs and OTC Drugs) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Generation
By Prescription Type
Prescription Drugs
OTC Drugs
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Cephalosporin Drugs Market Trends

This section covers the major market trends shaping the Cephalosporin Drugs Market according to our research experts:

The Fifth-generation Segment is Expected to Witness Healthy Growth Over the Forecast Period

The fifth-generation cephalosporins are found to be developed in the lab to specifically target resistant strains of bacteria. The fifth-generation cephalosporins include ceftobiprole, ceftaroline, and ceftolozane. These agents are sometimes referred to as the advanced generation, rather than the fifth-generation cephalosporins. Cephalosporins exhibit side effects similar to penicillin, along with drug allergy and hypersensitivity. Cephalosporins in general have been associated with little hepatotoxicity and rare instances of drug-induced liver injury. The ceftobiprole is found to be effective against methicillin-resistant Staphylococcus aureus (MRSA). The burden of infectious diseases across the world is increasing, which is resulting in the rising focus on diagnosis and treatment of the same.

Ceftobiprole has antipseudomonal characteristics that appear to be less susceptible to the development of resistance. Ceftaroline has also been described as the fifth-generation cephalosporin but does not have the antipseudomonal or VRE coverage of ceftobiprole. According to the study titled "Characterization and Clonal Diffusion of Ceftaroline Non-Susceptible MRSA in two Hospitals in Central Italy" published in the MDPI Antibiotics in August 2021, a novel cephalosporin with a low prevalence of resistance, ceftaroline is very effective against MRSA. Penicillin-binding protein (PBP) mutations and hospital clones of MRSA, such as CC5, CC8, or CC22, were among the resistance mechanisms. The fact that fifth-generation cephalosporins are effective against MRSA infections contracted in hospitals and that the number of infectious diseases is rising sharply as well as longer hospital stays is supporting the market's expansion.

According to the article “The new fifth generation cephalosporins-a balance between safety and efficacy,” published in December 2020, ceftaroline fosamile, the combination ceftolozane/tazobactame, and ceftobiprole medocaril are the first representatives of the fifth-generation of cephalosporins used in therapy. These new antibiotics are valuable anti-infective agents with a positive balance between benefits and side effects. Thus, the studied segment is expected to drive the growth of the cephalosporins market in the forecast period.​

The market is found growing as it has opened gates for an alternative for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Furthermore, ceftolozane is also combined with the β-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all β-lactam antibiotics, unless this enzyme is inhibited. Hence, the rising use of combination therapies may drive the market during the forecast period.

Thus, owing to above-mentioned factors it is expected to drive segment growth over the forecast period.


North America is Expected to be the Largest Growing Segment in the Global Market

North America is expected to witness high growth due to the rising prevalence of infectious diseases, increasing healthcare expenditure, and a large population base. Furthermore, cefuroxime is a second-generation cephalosporin antibiotic that has a broad-spectrum activity and is commonly used for the treatment of both upper and lower respiratory tract infections, Lyme disease, and genitourinary tract infections. It is readily available and affordable, and it exists in both oral and parenteral forms. According to the Center for Disease Control and Prevention (CDC), during the year 2020, the number of new tuberculosis cases found in the United States was around 7,174, a rate of 2.2 per 100,000 persons, which are significantly high. Thus, the growing burden of infectious diseases is anticipated to boost market growth.

The market for cephalosporin medications is anticipated to rise over the projected period as a result of an increase in funding for research and development (R&D) of cephalosporin pharmaceuticals and antibiotics. For instance, in May 2022, CARB-X received up to USD 300 million over ten years from the Biomedical Advanced Research and Development Authority (BARDA), a division of the United States Department of Health and Human Services. Up to USD 70 million will be provided over three years by Wellcome, a global charity organization that promotes biomedical research to fight antibiotic resistance. Both contributed USD 355 million in the project's first six years as original backers. Therefore, such efforts by various organizations to develop antibiotics promote the market's expansion over the forecast period.

Furthermore, strategic activities adopted by the market players such as product launches, mergers, and acquisitions are expected to expand the market. For instance, in October 2021, Sandoz acquired GSK’s cephalosporin antibiotics business. Through this acquisition, the company has acquired rights to three established brands (Zinnat, Zinacef, and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.​

Also, there is an increase in consumption of cephalosporin, easier availability, a rise in demand for over-the-counter drugs, and an increase in bacterial infection in the region that helps in driving the market growth.

Cephalosporin Drugs Market- Growth Rate By Region

Cephalosporin Drugs Market Competitor Analysis

The Cephalosporin Drugs Market is fragmented in terms of competition, owing to the presence of many small and large companies. There are also various collaborations, agreements, partnerships, and new product launches that are some of the important strategies adopted by the market players. Some of the well-known players in the market studied include Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd, Mankind Pharma, Merck & Co. Inc., Pfizer Inc., and Teva Pharmaceuticals. The increasing number of clinical trials for R&D of cephalosporin drugs by these companies is expected to propel the growth of the cephalosporin drugs market over the forecast period.

Cephalosporin Drugs Market Top Players

  1. Baxter International

  2. GlaxoSmithKline PLC

  3. Lupin Pharmaceuticals Inc.

  4. Pfizer Inc.

  5. Teva Pharmaceutical Industries Ltd

*Disclaimer: Major Players sorted in no particular order


Cephalosporin Drugs Market Recent Developments

  • In July 2022, Mast has launched the Ceftobiprole 5µg to the MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera/Mabelio) is a broad spectrum 5th generation Cephalosporin indicated in a number of countries in Europe for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Ceftobiprole is an effective option for targeted empirical therapy due to its broad spectrum of activity, its potent activity against methicillin-resistant Staphylococcus aureus (MRSA), and its good safety profile.
  • In February 2021, Novartis' generics division Sandoz signed an agreement with British drugmaker GlaxoSmithKline (GSK) to acquire its cephalosporin antibiotics brands for up to USD 500 million.

Cephalosporin Drugs Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Demand for Anti-microbials in Various Indications

      2. 4.2.2 Rising Prevalence of Infectious Diseases

      3. 4.2.3 Increase in Funding for the Development of Antibiotics

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Guidelines

      2. 4.3.2 Side Effects Associated with Cephalosporin

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Generation

      1. 5.1.1 First-generation

      2. 5.1.2 Second-generation

      3. 5.1.3 Third-generation

      4. 5.1.4 Fourth-generation

      5. 5.1.5 Fifth-generation

    2. 5.2 By Prescription Type

      1. 5.2.1 Prescription Drugs

      2. 5.2.2 OTC Drugs

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Baxter International

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 GlaxoSmithKline PLC

      4. 6.1.4 Lupin Pharmaceuticals Inc.

      5. 6.1.5 Macleods Pharmaceuticals Ltd

      6. 6.1.6 Mankind Pharma

      7. 6.1.7 Merck & Co. Inc.

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Teva Pharmaceutical Industries Ltd

      10. 6.1.10 Bristol-Myers Squibb Company

      11. 6.1.11 Eli Lilly and Company

      12. 6.1.12 Sun Pharmaceutical

      13. 6.1.13 Abbvie Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Cephalosporin Drugs Market Research FAQs

The Global Cephalosporin Drugs Market is studied from 2018 - 2028.

The Global Cephalosporin Drugs Market is growing at a CAGR of 2.75% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2018 - 2028.

North America holds highest share in 2021.

Baxter International, GlaxoSmithKline PLC, Lupin Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd are the major companies operating in Global Cephalosporin Drugs Market.

Global Cephalosporin Drugs Industry Reports

In-depth industry statistics and market share insights of the Global Cephalosporin Drugs sector for 2020, 2021, and 2022. The Global Cephalosporin Drugs research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Global Cephalosporin Drugs report PDF.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!